Drug Profile
EDC 2
Alternative Names: EDC-2; EDC-22Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Wisconsin Alumni Research Foundation
- Developer Centrose
- Class Drug conjugates; Immunoconjugates; Monoclonal antibodies; Small molecules
- Mechanism of Action Adenosine triphosphatase inhibitors; Cytoadhesin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Head and neck cancer
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Head and neck cancer in USA (Transdermal) (Centrose Pharma pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Head-and-neck-cancer in USA (Transdermal, Patch)
- 01 Aug 2017 Centrose has patent protection for extracellular drug conjugate technology in Japan